Fruquintinib
Last Updated: 04/28/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 264 publications
Expert opinion on treatment patterns in metastatic colorectal cancer management in Eastern Europe.
Journal: BMC proceedings
Published: March 23, 2026
Fruquintinib in combination with tislelizumab versus trifluridine/tipiracil and bevacizumab in third-line and beyond MSS mCRC without active liver metastases-the IKF-080/AIO-QUINTIS trial.
Journal: ESMO gastrointestinal oncology
Published: March 19, 2026
A Multifunctional Calcium Phosphate Nanoplatform Inducing Synergistic Copper/Calcium Overload and Antiangiogenesis for Enhanced Cancer Therapy.
Journal: ACS nano
Published: March 07, 2026
Multikinase inhibitors in refractory metastatic colorectal cancer: an optimal sequence?
Journal: Clinical advances in hematology & oncology : H&O
Published: February 20, 2026
Analysis of fruquintinib in patients with metastatic colorectal cancer who were enrolled in Spain: results from the global FRESCO-2 study.
Journal: ESMO gastrointestinal oncology
Published: February 06, 2026
Managing adverse events in patients with metastatic colorectal cancer receiving trifluridine/tipiracil in combination with bevacizumab.
Journal: ESMO gastrointestinal oncology
Published: February 06, 2026
Possible Fruquintinib Associated Ischemic Colitis in a Patient with Metastatic Ampullary Adenocarcinoma.
Journal: European journal of case reports in internal medicine
Published: January 26, 2026
Real-world pharmacovigilance and molecular mechanisms of fruquintinib: SRC and STAT3 as potential off-target mediators of proteinuria.
Journal: Frontiers in pharmacology
Published: January 26, 2026
HPLC-UV Analysis of Fruquintinib in Plasma of a Patient with Colorectal Cancer.
Journal: Biological & pharmaceutical bulletin
Published: January 18, 2026
Refractory microsatellite-stable metastatic colorectal cancer: a comparison between botensilimab + balstilimab and current standard of care.
Journal: Immuno-oncology technology
Published: January 08, 2026
Translating FRESCO clinical trial evidence into practice: fruquintinib as post-standard third-line therapy followed by trifluridine/tipiracil in a patient with mCRC without targetable mutations.
Journal: Clinical advances in hematology & oncology : H&O
Published: December 30, 2025
Current advances in colorectal cancer treatment: a review of recent clinical trials.
Journal: Expert opinion on pharmacotherapy
Published: December 20, 2025
Last Updated: 04/28/2026